The Recurrent Malignant Glioma drugs in development market research report provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Recurrent Malignant Glioma . Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued products.

GlobalData tracks 12 drugs in development for Recurrent Malignant Glioma by 12 companies/universities/institutes. The top development phase for Recurrent Malignant Glioma is phase i with five drugs in that stage. The Recurrent Malignant Glioma pipeline has seven drugs in development by companies and five by universities/ institutes. Some of the companies in the Recurrent Malignant Glioma pipeline products market are: Candel Therapeutics, Rockefeller University and Sumitomo Pharma.

The key targets in the Recurrent Malignant Glioma pipeline products market include Cells Expressing Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1), Cells Expressing Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1), and Cells Expressing Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21).

The key mechanisms of action in the Recurrent Malignant Glioma pipeline product include Cytotoxic To Cells Expressing Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) with two drugs in Phase II. The Recurrent Malignant Glioma pipeline products include seven routes of administration with the top ROA being Intravenous and five key molecule types in the Recurrent Malignant Glioma pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.

Recurrent Malignant Glioma overview

Recurrent malignant glioma is defined as the recurrence of a glioma tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord, and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy.

For a complete picture of Recurrent Malignant Glioma ‘s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.